$A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma$

A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Abstract Background ONC201 is a small molecule that can cause nonapoptotic cell death through loss of mitochondrial function. Results from the phase I/II trials of ONC201 in patients with refractory solid tumors demonstrated tumor responses and prolonged stable disease in some patients. Methods This...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2023-10, Vol.28 (10), p.919-e972
Hauptverfasser:	Atkins, Sarah L P, Greer, Yoshimi Endo, Jenkins, Sarah, Gatti-Mays, Margaret E, Houston, Nicole, Lee, Sunmin, Lee, Min-Jung, Rastogi, Shraddha, Sato, Nahoko, Burks, Christina, Annunziata, Christina M, Lee, Jung-Min, Nagashima, Kunio, Trepel, Jane B, Lipkowitz, Stanley, Zimmer, Alexandra S
Format:	Artikel
Sprache:	eng
Schlagworte:	Antimitotic agents Antineoplastic agents Antineoplastic Agents - adverse effects Care and treatment Cell death Clinical Trial Results Diagnosis Dosage and administration Endometrial cancer Endometrial Neoplasms - drug therapy Female Health aspects Humans Metastasis Neoplasm Recurrence, Local - drug therapy Risk factors Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - pathology
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!